Viewing nowVidio Tablets 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Withus Pharmaceuticals Co., Ltd.

MFDS item code 202001920 · Approved 2020.03.19 · Insurance code 660703370
Treatment of essential hypertension, improvement of heart failure, and reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension. It is also used for heart failure patients who are intolerant to ACE inhibitors, especially those classified as NYHA class II to IV. It helps reduce the risk of mortality after myocardial infarction and aids patients with reduced left ventricular function. This medication is effective in improving symptoms of heart failure and maintaining cardiovascular health. Therefore, it is used for management of hypertension, heart failure, and post-myocardial infarction care.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as experience with its use in these patients is lacking. 5. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so discontinue immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant and breastfeeding mothers should not use this medication; it is advisable to avoid use during breastfeeding as well. Do not use in patients with allergies to this medication, severe liver disease, cirrhosis, biliary obstruction, severe kidney impairment, or primary hyperaldosteronism. Elderly patients or those with high potassium levels, impaired liver function, heart valve diseases, or cardiovascular diseases should use this medication with caution. Especially in patients with heart failure or after myocardial infarction, renal function changes should be monitored carefully, and dosage should be adjusted if blood pressure drops too low. When starting this medication, blood pressure may drop suddenly, leading to dizziness or fainting, so it is recommended to start with a low dose and observe the patient's condition. Patients undergoing blood dialysis or those on diuretics, as well as patients on strict salt restrictions, need special caution during administration. This medication can increase blood potassium levels when used with other antihypertensives, some diuretics, or potassium-sparing diuretics, so care should be taken. Taking this medication with non-steroidal anti-inflammatory drugs may reduce blood pressure-lowering effects or worsen kidney function, so caution is necessary. Dizziness or drowsiness may occur during treatment, so caution is needed when driving or operating machinery. In case of overdose, symptoms such as low blood pressure, decreased consciousness, and shock may occur, requiring immediate medical attention. The safety and efficacy of this medication have not been established in children and adolescents, so it is recommended not to use it in individuals under 18 years of age. When storing, keep it out of reach of children and do not transfer to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Pink round film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Withus Pharmaceuticals Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.